ライフサイエンスコーパス: oropharyngeal

1 rectal (16.2%), followed by urine (5.4%) and oropharyngeal (0.7%) sites.

2 al (10/201), 11.1% rectal (18/162), and 7.5% oropharyngeal (15/201); chlamydia, 5.0% urogenital (10/2

3 al (10/201), 11.7% rectal (19/162), and 1.5% oropharyngeal (3/201).

4 Men and women had similar oropharyngeal (36.4vs.37.3;p=0.13) and anorectal (34.2vs

5 ovirus was detected in 94% of rectal, 79% of oropharyngeal, 56% of nasopharyngeal, and 20% of cerebro

6 ighest for rectal sites (10.4%), followed by oropharyngeal (9.7%) and urine (1.9%) sites.

7 Nasopharyngeal and oropharyngeal (adults only) swabs underwent culture for

8 astrointestinal osmosensory information with oropharyngeal and blood-borne signals.

9 of various cancers including penile, vulva, oropharyngeal and cervical cancers.

10 elopmental pathologic mechanisms also target oropharyngeal and cranial nerve differentiation.

11 Oropharyngeal and hypopharyngeal cancer made up the larg

12 The absolute risks of oropharyngeal and hypopharyngeal cancers were generally

13 ffects on growth, adhesion, and virulence of oropharyngeal and lung isolates of E. coli, suggesting t

14 Here we show that combined oropharyngeal and nasal infection of young (3- to 7-wk-o

15 For oral, oropharyngeal and oesophageal cancer, the early detectio

16 pression levels of PARP1 and to detect oral, oropharyngeal and oesophageal tumours in mice, pigs and

17 ice correctly classified all nasopharyngeal, oropharyngeal and sputum samples from 75 patients with C

18 A viruses that are responsible for cervical, oropharyngeal, and various genitourinary cancers.

19 To address this gap, we developed an oropharyngeal aspiration model of lethal and sublethal S

20 extracted, chemically analyzed, and given by oropharyngeal aspiration to mice or cultured with lung s

21 citrate-coated AgNPs or citrate buffer using oropharyngeal aspiration.

22 xposed to MWCNTs (10 or 40 microg/mouse) via oropharyngeal aspiration.

23 HPV attributable oropharyngeal cancer (HPV-OPC) incidence is increasing i

24 Human papilloma virus-16 (HPV-16) associated oropharyngeal cancer (HPVOPC) is increasing alarmingly i

25 independent causal effect of smoking on oral/oropharyngeal cancer (IVW OR 2.6, 95% CI = 1.7, 3.9 per

26 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime smokers wi

27 ents with human papillomavirus (HPV)-related oropharyngeal cancer (OPC) generally present with more a

28 rasts in HPV-attributable fractions (AFs) in oropharyngeal cancer (OPC) have not been evaluated in de

29 iation with or without chemotherapy to treat oropharyngeal cancer (OPC) is supported by evidence from

30 deintensification in the management of p16+ oropharyngeal cancer (OPC).

31 nsible for the rising worldwide incidence of oropharyngeal cancer (OPC).

32 ave achieved limited success in HPV-positive oropharyngeal cancer (OPC).

33 women were over-represented among women with oropharyngeal cancer (OR, 3.2; 95% CI, 1.7 to 6.0).

34 also related to the increasing incidence of oropharyngeal cancer among young men.

35 s been implicated in the rising incidence of oropharyngeal cancer and has led to variety of studies e

36 human papillomavirus 16 (HPV16) and HPV18 in oropharyngeal cancer and hepatitis B and C viruses in li

37 e recurrence in patients with HPV-associated oropharyngeal cancer and may facilitate earlier initiati

38 Oropharyngeal cancer associations were limited to the hu

39 tivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in

40 study included patients with non-metastatic oropharyngeal cancer from seven cancer centres located a

41 curve (AUC) were 0.70 or higher, except for oropharyngeal cancer in men.

42 Oropharyngeal cancer incidence is rapidly rising due to

43 Many prognostic algorithms for oropharyngeal cancer incorporate HPV status as a stratif

44 Human papillomavirus-related (HPV+) oropharyngeal cancer is a rapidly emerging disease with

45 Our proposed ICON-S staging system for HPV+ oropharyngeal cancer is suitable for the 8th edition of

46 The International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) aimed

47 d system, the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S); and a

48 associated with oral cavity cancer risk and oropharyngeal cancer risk, respectively.

49 portance of human leukocyte antigen loci for oropharyngeal cancer risk, suggesting that immunologic m

50 Of 1907 patients with HPV+ oropharyngeal cancer, 661 (35%) were recruited at the tr

51 dence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patien

52 A total of 84% of the patients had oropharyngeal cancer, and 75% had tumor specimens that s

53 incidence data for cervical adenocarcinoma, oropharyngeal cancer, and anal cancer.

54 Human papillomavirus-associated oropharyngeal cancer, in particular, is increasing in in

55 PV) integration into the host genome in oral/oropharyngeal cancer, reviewed the literature for HPV-in

56 rade 3, and 5.51 (95% CI, 1.22 to 24.84) for oropharyngeal cancer.

57 evelop a TNM classification specific to HPV+ oropharyngeal cancer.

58 derive new staging classifications for HPV+ oropharyngeal cancer.

59 ical cancer and a major cause of genital and oropharyngeal cancer.

60 , the presumed precursor of HPV16-associated oropharyngeal cancer.

61 al oncogenic HPV infections and HPV-positive oropharyngeal cancers among men than women arises in par

62 ence of human papilloma virus (HPV)-positive oropharyngeal cancers has risen rapidly in recent decade

63 -intensification regimens for HPV-associated oropharyngeal cancers in populations with high tobacco c

64 papillomavirus (HPV) causes the majority of oropharyngeal cancers in the United States, yet the risk

65 dence of human papillomavirus (HPV)-positive oropharyngeal cancers is higher and increasing more rapi

66 ian males with advanced-stage HPV-associated oropharyngeal cancers suggests pervasive tobacco consump

67 ned to human papillomavirus (HPV)-associated oropharyngeal cancers, specifically the oropharynx subsi

68 an papillomavirus (HPV) cause anogenital and oropharyngeal cancers, whereas cutaneous types (e.g. HPV

69 V-16) and HPV-18 cause a large proportion of oropharyngeal cancers, which are increasing in incidence

70 PVs) are causative agents in ano-genital and oropharyngeal cancers.

71 s (HPVs) are a major cause of anogenital and oropharyngeal cancers.

72 worldwide, notably cervical, anogenital, and oropharyngeal cancers.

73 tained current data for HPV-related oral and oropharyngeal cancers.

74 a major cause of noncervical anogenital and oropharyngeal cancers.

75 fection, the principal cause of HPV-positive oropharyngeal cancers.

76 pe associated with cervical, anogenital, and oropharyngeal cancers.

77 ive agents of cervical, anal as well as many oropharyngeal cancers.

78 and reducing the morbidity of treatments for oropharyngeal cancers.

79 ausative agents of anogenital tract and some oropharyngeal cancers.

80 ers and a proportion of other anogenital and oropharyngeal cancers.

81 -17 receptor (IL-17R) is required to prevent oropharyngeal candidiasis (OPC) in mice and humans.

82 Oropharyngeal candidiasis (OPC) is an opportunistic infe

83 nic, clinically manifesting most commonly as oropharyngeal candidiasis and vulvovaginal candidiasis (

84 One important line of defense against oropharyngeal candidiasis is the oral microbiota that pr

85 and reduced interleukin-17 signalling during oropharyngeal candidiasis, resulting in more severe dise

86 ly induce EGFR phosphorylation during murine oropharyngeal candidiasis.

87 tion, and fungal burden in a murine model of oropharyngeal candidiasis.

88 ard Candida albicans, the causative agent of oropharyngeal candidiasis.

89 Human papillomavirus-related oropharyngeal carcinoma (HPV-OPC) is increasing in incid

90 Using human papillomavirus-related oropharyngeal carcinoma as a model, we show aberrant enr

91 human papillomavirus is well established in oropharyngeal carcinoma, it has not been proven in the p

92 For patients with HPV-positive oropharyngeal carcinoma, radiotherapy plus cetuximab sho

93 tolerability for patients with HPV-positive oropharyngeal carcinoma.

94 care for eligible patients with HPV-positive oropharyngeal carcinoma.

95 cluded histologically confirmed HPV-positive oropharyngeal carcinoma; American Joint Committee on Can

96 The primary outcome was oropharyngeal carriage of disease-causing Neisseria meni

97 ncidence as well as significant reduction of oropharyngeal carriage of group A meningococci in vaccin

98 Asymptomatic oropharyngeal carriage of Neisseria meningitidis peaks i

99 le approach using summary data on 6,034 oral/oropharyngeal cases and 6,585 controls from a recent gen

100 Stratified analyses on a subgroup of oropharyngeal cases with information available on human

101 ed that competent epithelium spread into the oropharyngeal cavity via the mouth and other possible ch

102 ells derived from the periderm penetrate the oropharyngeal cavity via the mouth and via the endoderma

103 idin could be of clinical interest to reduce oropharyngeal colonization and prevent lung infection.

104 Concurrent nasal and/or oropharyngeal colonization was also associated with an i

105 k factors in women, clinical significance of oropharyngeal CT detection, acceptability and performanc

106 (SN) biopsy is accurate in operable oral and oropharyngeal cT1-T2N0 cancer (OC), but, to our knowledg

107 For thirst, oropharyngeal cues have a critical role in driving satia

108 Anterior nares and oropharyngeal cultures were collected.

109 elective digestive decontamination/selective oropharyngeal decontamination and those receiving standa

110 tive digestive decontamination and selective oropharyngeal decontamination in 16 ICUs in The Netherla

111 ropharyngeal prophylactic methods (selective oropharyngeal decontamination, patient position, sinusit

112 elective digestive decontamination/selective oropharyngeal decontamination.

113 clefting leads to muscle misorientation and oropharyngeal deficiency and adversely affects speech, s

114 oropharyngeal duck samples; however, taking oropharyngeal duck samples was estimated to be more effe

115 s for detecting AIVs subtypes H5N1 and H5N6: oropharyngeal duck samples, solid and liquid wastes, pou

116 ved the collection of both environmental and oropharyngeal duck samples.

117 ecting H5N1 viruses is equivalent to that of oropharyngeal duck samples; however, taking oropharyngea

118 Considering that neurogenic oropharyngeal dysphagia is a prevalent condition with or

119 stinguishing true oesophageal dysphagia from oropharyngeal dysphagia or other causes.

120 between 41 and 75 years old] with neurogenic oropharyngeal dysphagia regardless of gender.

121 control of HR in this group of subjects with oropharyngeal dysphagia.

122 ariability (HRV) in subjects with neurogenic oropharyngeal dysphagia.

123 to characterize the diversity of viruses in oropharyngeal epithelia, germinal centers, probang sampl

124 Mild-to-moderate oropharyngeal events were the most common side-effect, r

125 ory tract will contain smaller quantities of oropharyngeal flora and be more likely to have a predomi

126 Using isolation of low quantities of oropharyngeal flora and higher prevalence of potential p

127 rom induced sputum specimens and quantity of oropharyngeal flora were compared for different quantiti

128 The quantities of viral RNA shed in oropharyngeal fluid during FMDV persistence were similar

129 imprecise innervation leading to inefficient oropharyngeal function associated with 22q11.2 deletion

130 ruption of cranial nerve differentiation and oropharyngeal function in LgDel mice.

131 major source of innervation for appropriate oropharyngeal function, underlies this departure from ty

132 reened for syphilis, urogenital, rectal, and oropharyngeal gonorrhea/chlamydia, respectively.

133 reened for syphilis, urogenital, rectal, and oropharyngeal gonorrhea/chlamydia, respectively.

134 increased awareness of the high frequency of oropharyngeal gonorrhoea.

135 sarcomas and highest for cervical cancer and oropharyngeal head and neck cancer.

136 mmunity from female-only vaccination against oropharyngeal HPV infection in contemporaneously aged ma

137 Clearance of anogenital and oropharyngeal HPV infections is attributed primarily to

138 In contrast, prevalence of any oropharyngeal HPV type was similar in vaccinated and unv

139 is associated with significant reductions in oropharyngeal HPV-16 infections.

140 Oropharyngeal HPV-16 prevalence in unvaccinated males wa

141 Overall, oropharyngeal HPV-16 prevalence was significantly lower

142 Severe oropharyngeal injuries (P = 0.015), increased levels of

143 tered 2 or 4 g/kg of ethanol 30 min prior to oropharyngeal inoculation of 2 x 10(7) CFU of USA300.

144 zard ranking was validated in mouse lungs by oropharyngeal instillation of six randomly selected MeON

145 reported with 4.8% of doses, with transient oropharyngeal itching reported most commonly.

146 gher in patients with submucosal (abdominal, oropharyngeal-laryngeal) attacks (3095 [890-10000] mug/l

147 e velum (86%), followed by the tongue (57%), oropharyngeal lateral wall (49%), and epiglottis (26%).

148 h high (>6.9 log10 copies/mL) nasopharyngeal/oropharyngeal load and C-reactive protein >/=40 mg/L (bo

149 activity and follicular immunoreactivity in oropharyngeal lymphoid tissues at 1 and 2 months postexp

150 l phase of prion amplification occurs in the oropharyngeal lymphoid tissues followed by rapid dissemi

151 th initial prion replication in the draining oropharyngeal lymphoid tissues, rapidly followed by diss

152 lomaviruses (HPVs) that cause anogenital and oropharyngeal malignancies must simultaneously activate

153 pically following orogenital contact with an oropharyngeal meningococcal carrier.

154 outbreak at a U.S. college, we profiled the oropharyngeal microbiomes of 158 students to identify as

155 in the largest longitudinal study of the CF oropharyngeal microbiota.

156 miR-155 was significantly upregulated in the oropharyngeal mucosa during chronic SIV infection and wa

157 innate and adaptive immune responses at the oropharyngeal mucosa.

158 Here, the authors show that oropharyngeal mucosal infection of macaques with a high

159 m outcomes, more rapid engraftment, and less oropharyngeal mucositis, the combination of Tac/Sir is a

160 number of species, but was distinct from the oropharyngeal mycobiota and air samples.

161 Routine universal testing detected more oropharyngeal N. gonorrhoeae infections than selective t

162 Independent risk factors for oropharyngeal N. gonorrhoeae were assessed among MSM rou

163 Routine universal testing detected more oropharyngeal N.gonorrhoeae infections compared to selec

164 (n=10/201), 11.1% rectal(n=18/162), and 7.5% oropharyngeal(n=15/201); chlamydia: 5.0% urogenital(n=10

165 l(n=10/201), 11.7% rectal(n=19/162) and 1.5% oropharyngeal(n=3/201).

166 fastidious, Gram-negative bacterium with an oropharyngeal/nasopharyngeal carriage niche that is asso

167 ic biological media (e.g., blood, saliva and oropharyngeal/nasopharyngeal swab) through interaction w

168 The majority of oropharyngeal Neisseria gonorrhoeae infections are asymp

169 Most oropharyngeal Neisseria gonorrhoeae infections are asymp

170 Independent risk factors for oropharyngeal Neisseria gonorrhoeae were assessed among

171 Recent use of any antibiotics may select for oropharyngeal Neisseria species with antimicrobial resis

172 Nasopharyngeal and oropharyngeal (NP/OP) specimens were collected from the

173 on by multiplex PCR in IS and nasopharyngeal/oropharyngeal (NP/OP) specimens.

174 nostic platforms often use nasopharyngeal or oropharyngeal (NP/OP) swabs for pathogen detection for p

175 Nasopharyngeal/oropharyngeal (NP/OP) swabs from 70 children <5 years wi

176 However, nasopharyngeal/oropharyngeal (NP/OP) swabs may not accurately reflect e

177 stigating pathogens in blood, nasopharyngeal/oropharyngeal (NP/OP) swabs, and induced sputum by cultu

178 pneumococcal carriage and nasopharyngeal and oropharyngeal NTHi carriage in 13 541 samples collected

179 ve testing, of which more than half would be oropharyngeal only.

180 The proportion of oropharyngeal-only infections was 55% and 47% respective

181 Proportions of oropharyngeal-only infections were 55% and 47%, respecti

182 ve testing, of which more than half would be oropharyngeal-only.

183 VA)-sensitized BALB/cJ mice were exposed via oropharyngeal (OP) aspiration to 20 or 100 mug of each P

184 compared to "RSV pneumonia" (nasopharyngeal/oropharyngeal or induced sputum PCR-positive without con

185 tion of beta1-HPV-5 type was associated with oropharyngeal (OR, 7.42; 95% CI, 0.98-56.82; P = .054),

186 ometrial, laryngeal, lung, melanoma, oral or oropharyngeal, ovarian, prostate, rectal, and renal canc

187 comparable titers in chickens, with superior oropharyngeal over cloacal shedding; both viruses transm

188 Nasopharyngeal and oropharyngeal paired samples (599 each) of individuals o

189 COVID-19, and 29 either were nasopharyngeal/oropharyngeal PCR negative or presented for reasons unre

190 The two stool PCR-positive, nasopharyngeal/oropharyngeal PCR-negative patients were SARS-CoV-2 IgG

191 ainage, silver-coated endotracheal tubes) or oropharyngeal prophylactic methods (selective oropharyng

192 as and premalignancies of the anogenital and oropharyngeal region after a CIN3 diagnosis.

193 plays crucial roles in the patterning of the oropharyngeal region and development of muscles derived

194 ional significance of Dlx5 in patterning the oropharyngeal region has remained unknown.

195 This study aimed to evaluate posterior oropharyngeal saliva (POPS) for severe acute respiratory

196 of qPCR improved detection of pneumococci in oropharyngeal samples compared to CCBM: from 0.7% to 10.

197 CV-1 were found in a significant fraction of oropharyngeal samples from a healthy human cohort.

198 It was recently reported that 44% of the oropharyngeal samples from the healthy humans in a study

199 Serial oropharyngeal samples were taken over a 30-day period, a

200 sence of azithromycin-resistant organisms in oropharyngeal samples, along with adverse events, were a

201 CI, 2.2-22.6), with positive association for oropharyngeal SCC (OR, 22.4; 95% CI, 1.8-276.7), but not

202 cell carcinoma (SCC), and the prevalence of oropharyngeal SCC is higher among men than women in the

203 We used a combination of an oropharyngeal SCC tissue microarray, HNSCC cell lines, a

204 therapy in human papilloma virus-associated oropharyngeal SCC, we hypothesized that adding cetuximab

205 t HPV-16 detection precedes the incidence of oropharyngeal SCC.

206 ing sex differences in risk for HPV-positive oropharyngeal SCC.

207 pithelia, germinal centers, probang samples (oropharyngeal scrapings), and tonsil swabs to determine

208 This study aimed to determine if sampling of oropharyngeal secretions (OSs) helps improves detection

209 roken skin and/or mucosa with saliva, tears, oropharyngeal secretions, cerebrospinal fluid, and neura

210 The quantity of oropharyngeal shedding by contacts was associated with H

211 nce of a sustained cloacal shedding (and not oropharyngeal shedding) was critical for transmission.

212 discontinued treatment primarily because of oropharyngeal side-effects, apomorphine sublingual film

213 d progression to cancer at both cervical and oropharyngeal sites as these appear to be distinct.

214 man papillomavirus 16 infects anogenital and oropharyngeal sites, the cervical epithelium has a uniqu

215 rgets are associated with differences in the oropharyngeal skeleton and autonomic nervous system of l

216 nasal specimens and either nasopharyngeal or oropharyngeal specimens from 251 participants with COVID

217 Nasopharyngeal/oropharyngeal specimens were tested for HBoV mRNA and ge

218 se chain reaction analysis of nasopharyngeal/oropharyngeal specimens.

219 riminates poorly when applied to HPV-related oropharyngeal squamous cell cancer (OPSCC), leading to c

220 our pipeline to human papillomavirus-related oropharyngeal squamous cell carcinoma (HPV + OPSCC).

221 The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been r

222 idence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) has been r

223 The incidence of HPV-related oropharyngeal squamous cell carcinoma (OPSCC) has increa

224 Human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) has shown

225 A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence

226 Oropharyngeal squamous cell carcinoma (OPSCC) incidence

227 urden of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is disprop

228 Purpose Treatment of oropharyngeal squamous cell carcinoma (OPSCC) is evolvin

229 urpose Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is treatme

230 s the most important determinant of oral and oropharyngeal squamous cell carcinoma (OPSCC) outcomes,

231 les from TCGA and a separate dataset of HPV+ oropharyngeal squamous cell carcinoma (OPSCC) samples to

232 ence-based guideline on radiation therapy in oropharyngeal squamous cell carcinoma (OPSCC) that was d

233 ysis into the trace elemental composition of oropharyngeal squamous cell carcinoma (OPSCC), we perfor

234 ker of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).

235 sis of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OSCC).

236 mavirus genotype 16 (HPV16) infection causes oropharyngeal squamous cell carcinoma (SCC), and the pre

237 atients with human papillomavirus-associated oropharyngeal squamous cell carcinoma could maintain his

238 is the separate staging of viral-associated oropharyngeal squamous cell carcinoma from tobacco and a

239 nts with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma have high survival

240 and outcome in human-papillomavirus-positive oropharyngeal squamous cell carcinoma is particularly ne

241 criteria included patients with p16-positive oropharyngeal squamous cell carcinoma, smoking history o

242 therapy in human papilloma virus-associated oropharyngeal squamous cell carcinoma, we hypothesized t

243 ck squamous carcinoma (HNSCC)-in particular, oropharyngeal squamous cell carcinoma.

244 atients with human papillomavirus-associated oropharyngeal squamous cell carcinoma.

245 icrobial signatures unique to human oral and oropharyngeal squamous cell carcinomas (OCSCC/OPSCC).

246 Tobacco- or human papillomavirus- driven oropharyngeal squamous cell carcinomas (OpSCC) represent

247 ver, comparing HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas (OPSCC) we notice

248 nd neck (HNSCC), the increasing incidence of oropharyngeal squamous cell carcinomas (OPSCCs) is attri

249 causative agent for an increasing subset of oropharyngeal squamous cell carcinomas (OPSCCs), and cur

250 rus (HPV) causes an increasing proportion of oropharyngeal squamous cell carcinomas (OPSCCs), particu

251 rus (HPV) causes an increasing proportion of oropharyngeal squamous cell carcinomas (OPSCCs), particu

252 on declined, human papillomavirus-associated oropharyngeal squamous-cell carcinoma stabilized, and qu

253 satiation signals by liquid-gulping-induced oropharyngeal stimuli and gut osmolality sensing.

254 th either the general population or the post-oropharyngeal surgery population with relative risks of

255 Oropharyngeal swab cultures for meningococcal carriage w

256 were detected and characterized in naso- and oropharyngeal swab samples using a novel oligonucleotide

257 tudents recommended for vaccination provided oropharyngeal swab specimens and completed questionnaire

258 A total of 4225 oropharyngeal swab specimens from 3802 unique participan

259 Oropharyngeal swab specimens were collected weekly from

260 Results: The oropharyngeal swab test was positive for SARS-CoV-2.

261 The addition of an oropharyngeal swab, compared with use of a nasal swab al

262 e samples (32.5), anorectal swabs (34.0) and oropharyngeal swabs (36.8) (P<0.001).

263 Nasopharyngeal/oropharyngeal swabs (NOPS) from 7663 patients were prosp

264 Bacterial RNA extracted directly from oropharyngeal swabs and evaluated by quantitative revers

265 l evaluation and provided nasopharyngeal and oropharyngeal swabs and induced sputum (cases only) for

266 swabs had equal or greater sensitivity than oropharyngeal swabs for detection of respiratory syncyti

267 ary 2010-June 2012 and tested nasopharyngeal/oropharyngeal swabs for Mp using real-time polymerase ch

268 Nasopharyngeal/oropharyngeal swabs from children (1 to 59 months of age

269 e 9 developing country sites, nasopharyngeal/oropharyngeal swabs from children with and without pneum

270 and middle-income countries, nasopharyngeal/oropharyngeal swabs from children with severe pneumonia

271 pecimen types tested included nasopharyngeal/oropharyngeal swabs in the above-named transport media,

272 Nasal/ oropharyngeal swabs were collected and tested for RSV us

273 Nasopharyngeal and oropharyngeal swabs were collected during influenza-like

274 Venous blood and nasopharyngeal/oropharyngeal swabs were collected from all cases.

275 Naso- and oropharyngeal swabs were collected from persons with inf

276 Questionnaires and oropharyngeal swabs were collected from students.

277 ess were interviewed, and nasopharyngeal and oropharyngeal swabs were collected to detect respiratory

278 Naso- and oropharyngeal swabs were collected.

279 the added value of collecting both nasal and oropharyngeal swabs, compared with collection of nasal s

280 invasive swabbing methods, such as nasal and oropharyngeal swabs, had about the same sensitivity as d

281 polymerase chain reaction performed on nasal/oropharyngeal swabs.

282 important role in assisting the delivery of oropharyngeal swallowing exercises including jaw exercis

283 The development of oropharyngeal symptoms after initiating should alert the

284 Local reactions, such as gastrointestinal or oropharyngeal symptoms, are common.

285 of the facility underwent nasopharyngeal and oropharyngeal testing for SARS-CoV-2, including real-tim

286 Therefore, routine universal oropharyngeal testing in MSM is feasible and warranted,

287 Therefore, routine universal oropharyngeal testing in MSM is feasible and warranted,

288 testing when >=85% of consultations included oropharyngeal testing or as selective testing (<85% test

289 Oropharyngeal testing policy was defined as routine univ

290 Oropharyngeal testing policy was defined as routine univ

291 testing when >=85% of consultations included oropharyngeal testing, or as selective testing(<85% test

292 ical carcinoma and a subset of tumors in the oropharyngeal tract.

293 s, including those within the anogenital and oropharyngeal tracts.

294 a role for EBV as a cofactor in HPV-positive oropharyngeal tumors.

295 rgery is a new approach for the treatment of oropharyngeal tumors.

296 urred at highest frequency in oral cavity or oropharyngeal tumors.

297 ve the majority of genital cancers, and many oropharyngeal tumors.

298 ariants previously associated with two other oropharyngeal ulcerative disorders, Behcet's disease and

299 by, SARS-CoV-2 in sputum, nasopharyngeal or oropharyngeal, urine, stool, blood and environmental spe

300 ers mechanical upper airway obstruction from oropharyngeal weakness contributes equally to an increas